ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2021
The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review.Journal of the American Heart Association · 2021Pooled it
- WASOG Clinical Trial Endpoint Task Force: Executive Summary.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Myocardial-to-background ratio in F18-fluorodeoxyglucose PET in cardiac sarcoidosis for diagnosis and evaluation of therapeutic response.International journal of cardiology. Heart & vasculature · 2025Article
- The Mechanism and Natural History of Mitral Regurgitation in Cardiac Sarcoidosis.The American journal of cardiology · 2023Article
- Role of Imaging in Cardiomyopathies.Cardiac failure review · 2023Review
- Added value gated PET with phase analysis for the detection of scar burden and prognostication in cardiac sarcoidosis?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Myocardial perfusion imaging in cardiac sarcoidosis: A "sine qua non" for prognosis assessment?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Potential roles ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Cardiac Sarcoidosis: When and How to Treat Inflammation.Cardiac failure review · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis is a multisystemic disorder of unknown cause characterized by immune granuloma formation in the involved organs. Few studies have reported on the myocardial perfusion changes by immunosuppression therapy in cardiac sarcoidosis (CS). Additionally, the relationship between myocardial perfusion changes and prognosis is unknown. Therefore, this study aimed to clarify myocardial perfusion recovery after steroid therapy and its prognostic value for major adverse cardiac events (MACE) in patients with CS. METHODS AND
resultsThirty-eight consecutive patients with CS {median age, 63 [interquartile range (IQR) 51-68] years; 10 men} underwent both
conclusionsMyocardial perfusion was recovered by steroid therapy in 61% and preserved in 8% of patients. Myocardial perfusion recovery after steroid therapy was significantly associated with a low incidence of MACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.